Nautilus Biotechnology, Inc. (NAUT) Research

Nautilus Biotechnology, Inc. is an emerging life sciences firm dedicated to pioneering a platform technology aimed at quantifying and comprehensively understanding the intricate complexities of the proteome. Their flagship offering, the Nautilus Platform, is an integrated proteomics system. It provides a complete, end-to-end solution, including specialized instruments, essential consumables, and advanced software for data analysis. Based in Seattle, Washington, the company was established in 2016.

Market snapshot

Symbol
NAUT
Price
$2.28
Day change
+4.59%
Market cap
$289.7M
P/E ratio
-5.06x
52-week range
0.62-4.31
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$2.50

Peer companies

  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Assembly Biosciences, Inc. (ASMB)
  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Foghorn Therapeutics Inc. (FHTX)
  • Humacyte, Inc. (HUMA)
  • Immuneering Corporation (IMRX)
  • Pyxis Oncology, Inc. (PYXS)
  • Sagimet Biosciences Inc. (SGMT)

Recent insider activity

  • AH Equity Partners Bio II, L.L.C. — S-Sale (4615974 shares) on 2026-06-02
  • AH Equity Partners Bio II, L.L.C. — S-Sale (384026 shares) on 2026-06-02
  • Patel Sujal M — P-Purchase (25000 shares) on 2026-03-04
  • Mowry Anna — A-Award (160000 shares) on 2026-03-02
  • Mallick Parag — A-Award (280000 shares) on 2026-03-02

Open Nautilus Biotechnology, Inc. (NAUT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.